The 1-year PFS and 1-year OS rate were 45% and 67%, respectively. Median PFS and OS were 11.2 and 23 months. Any acute grade 2 toxicity was observed in four patients (15%) and grade 3 pulmonary toxicity in two patients (8%).
Overall metabolic response rate was 60% with seven patients (30%) achieving a complete metabolic remission and 7 (30%) a partial metabolic response. Twenty-six patients received SBRT after induction chemotherapy (n = 17) or as a primary treatment (n = 9). Side-effects were scored using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. The progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier method from start of chemotherapy or radiotherapy. Positron emission tomography-computed tomography (PET-CT) was carried out at baseline and 3 months after SBRT to evaluate the metabolic response rate according to PET Response Criteria in Solid Tumors (PERCIST). SBRT to a dose of 50 Gy in 10 fractions was delivered.
#STORME 2014 TRIAL#
Oligometastatic NSCLC patients with ≤5 metastatic lesions were included in a prospective phase II trial to evaluate efficacy and toxicity of SBRT to all disease sites, primary tumor and metastatic locations. The majority of patients included in SBRT trials for oligometastatic NSCLC have controlled primary tumors and brain metastases. SBRT is used as a local consolidative treatment to metastatic disease sites.
Stereotactic body radiotherapy (SBRT) has emerged as a treatment modality in patients presenting with oligometastatic nonsmall-cell lung cancer (NSCLC).
0 kommentar(er)
